Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Corvus Pharmaceuticals (CRVS) Shares Issued (2023 - 2025)

Corvus Pharmaceuticals has reported Shares Issued over the past 3 years, most recently at $67750.0 for Q3 2025.

  • Quarterly results put Shares Issued at $67750.0 for Q3 2025, up 100.91% from a year ago — trailing twelve months through Dec 2025 was $3.3 million (up 30.65% YoY), and the annual figure for FY2025 was $35.7 million, up 92.28%.
  • Shares Issued for Q3 2025 was $67750.0 at Corvus Pharmaceuticals, down from $2.9 million in the prior quarter.
  • Over the last five years, Shares Issued for CRVS hit a ceiling of $9.7 million in Q4 2024 and a floor of -$7.5 million in Q3 2024.
  • Median Shares Issued over the past 3 years was $303000.0 (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Shares Issued: tumbled 2384.71% in 2024 and later skyrocketed 100.91% in 2025.
  • Corvus Pharmaceuticals' Shares Issued stood at $327000.0 in 2023, then soared by 2852.91% to $9.7 million in 2024, then tumbled by 99.3% to $67750.0 in 2025.
  • The last three reported values for Shares Issued were $67750.0 (Q3 2025), $2.9 million (Q2 2025), and $279000.0 (Q1 2025) per Business Quant data.